☰

Joshua J. Oaks, Ph.D. - Publications

Affiliations: 
2013 Integrated Biomedical Science Graduate Program Ohio State University, Columbus, Columbus, OH 
Area:
Biomedical Engineering, Medicine and Surgery, Oncology, Pharmacology
Tree Info Similar researchers PubMed Report error

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 De Palma RM, Parnham SR, Li Y, Oaks JJ, Peterson YK, Szulc ZM, Roth BM, Xing Y, Ogretmen B. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201802264R. PMID 30917007 DOI: 10.1096/Fj.201802264R  0.383
2018 Wang H, Li S, Oaks J, Ren J, Li L, Wu X. The concerted roles of FANCM and Rad52 in the protection of common fragile sites. Nature Communications. 9: 2791. PMID 30022024 DOI: 10.1038/S41467-018-05066-Y  0.376
2018 Oaks J, Wang M, Zou H. Abstract 5623: Development of a CD47-blocking antibody as a cancer therapy Cancer Research. 78: 5623-5623. DOI: 10.1158/1538-7445.Am2018-5623  0.382
2015 Panneer Selvam S, De Palma RM, Oaks JJ, Oleinik N, Peterson YK, Stahelin RV, Skordalakes E, Ponnusamy S, Garrett-Mayer E, Smith CD, Ogretmen B. Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. Science Signaling. 8: ra58. PMID 26082434 DOI: 10.1126/Scisignal.Aaa4998  0.448
2014 Oaks J, Ogretmen B. Regulation of PP2A by Sphingolipid Metabolism and Signaling. Frontiers in Oncology. 4: 388. PMID 25642418 DOI: 10.3389/Fonc.2014.00388  0.48
2013 Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951  0.785
2013 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 122: 3034-44. PMID 23970380 DOI: 10.1182/Blood-2013-04-495374  0.723
2013 Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34. PMID 23926298 DOI: 10.1182/Blood-2013-03-492181  0.72
2013 Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia. 27: 1996-2005. PMID 23670294 DOI: 10.1038/Leu.2013.151  0.684
2013 Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Journal of Hematology & Oncology. 6: 21. PMID 23497456 DOI: 10.1186/1756-8722-6-21  0.662
2013 Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. Embo Molecular Medicine. 5: 105-21. PMID 23180565 DOI: 10.1002/Emmm.201201283  0.619
2012 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis J, Marcucci G, Landesman Y, Shacham S, Kauffman M, Perrotti D. Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL Blood. 120: 35-35. DOI: 10.1182/Blood.V120.21.35.35  0.753
2012 Walker C, Oaks JJ, Santhanam R, Neviani P, Harb JG, Paisie C, Marcucci G, Landesman Y, Shacham S, Kauffman M, Perrotti D. Abstract 3839: Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias Cancer Research. 72: 3839-3839. DOI: 10.1158/1538-7445.Am2012-3839  0.733
2011 Simon GR, Saddoughi S, Mukhopadhyay A, Peterson Y, Senkal CE, Oaks J, Perrotti D, Hannun Y, Ogretmen B. Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7574. PMID 28023125 DOI: 10.1200/Jco.2011.29.15_Suppl.7574  0.63
2011 Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 117: 5941-52. PMID 21527515 DOI: 10.1182/Blood-2010-08-300772  0.677
2011 Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Paisie C, Marcucci G, Shacham S, Kauffman M, Perrotti D. Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity, Blood. 118: 3758-3758. DOI: 10.1182/Blood.V118.21.3758.3758  0.76
2011 Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Neviani P, Harb JG, Ogretmen B, Bittman R, Levine RL, Quintás-Cardama A, Marcucci G, Perrotti D. FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration Blood. 118: 2494-2494. DOI: 10.1182/Blood.V118.21.2494.2494  0.735
2011 Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, et al. Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-109  0.788
2010 Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140: 652-65. PMID 20211135 DOI: 10.1016/J.Cell.2010.01.007  0.735
2010 Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Walker C, Neviani P, Harb JG, Ma Y, Verstovsek S, Marcucci G, Briesewitz R, Bittman R, Chen C, Quintas-Cardama A, Ogretmen B, et al. Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders Blood. 116: 775-775. DOI: 10.1182/Blood.V116.21.775.775  0.733
2010 Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, et al. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment Blood. 116: 515-515. DOI: 10.1182/Blood.V116.21.515.515  0.789
2010 Walker C, Oaks JJ, Neviani P, Harb JG, Santhanam R, Ma Y, Marcucci G, Van Brocklyn J, Chen C, Bittman R, Perrotti D. PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives Blood. 116: 2901-2901. DOI: 10.1182/Blood.V116.21.2901.2901  0.728
2010 Harb JG, Neviani P, Oaks JJ, Marcucci G, Hokland P, Roy D, Perrotti D. The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML. Blood. 116: 1222-1222. DOI: 10.1182/Blood.V116.21.1222.1222  0.668
2010 Eiring AM, Harb J, Neviani P, Oaks JJ, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, et al. Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors Cancer Research. 70: 1950-1950. DOI: 10.1158/1538-7445.Am10-1950  0.727
2009 Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner C, et al. Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors. Blood. 114: 855-855. DOI: 10.1182/Blood.V114.22.855.855  0.721
2009 Oaks J, Neviani P, Mukhopadhyay A, Santhanam R, Ma Y, Mao C, Marcucci G, Chen C, Cortes J, Caligiuri MA, Hokland P, Huettner C, Koschmieder S, Cancelas J, Briesewitz R, et al. FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor. Blood. 114: 3259-3259. DOI: 10.1182/Blood.V114.22.3259.3259  0.741
2008 Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 111: 816-28. PMID 17925491 DOI: 10.1182/Blood-2007-05-090472  0.777
2007 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/Jci31095  0.772
2007 Oaks JJ, Santhanam R, Briesewitz R, Perrotti D. Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders. Blood. 110: 3548-3548. DOI: 10.1182/Blood.V110.11.3548.3548  0.698
2007 Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis. Blood. 110: 33-33. DOI: 10.1182/Blood.V110.11.33.33  0.794
2006 Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy D, Caligiuri MA, Bloomfield CD, Chen C, et al. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. Blood. 108: 288-288. DOI: 10.1182/Blood.V108.11.288.288  0.786
2005 Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Chang J, Liu S, Mao H, Oaks JJ, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, et al. ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. Blood. 106: 1992-1992. DOI: 10.1182/Blood.V106.11.1992.1992  0.74
Show low-probability matches.